Clinical significance and prognostic value of tumor necrosis factor-α and dickkopf related protein-1 in ankylosing spondylitis

Table 1 General information

	Study group (n = 113)	Control group (n = 100)	P value
Sex, n (%)			0.159
Male	76 (67.26)	76 (76.00)
Female	37 (32.74)	24 (24.00)
Age (yr)	36.7 ± 4.1	37.3 ± 4.6	0.315
BMI (kg/m2)	22.25 ± 1.83	23.49 ± 2.16	0.381
Course of disease (yr)	1.5 ± 0.4
CRP (ng/L)
Before treatment	8.61 ± 0.72	0.50 ± 0.00	< 0.001
After treatment	1.32 ± 0.121
IgG (g/L)
Before treatment	16.00 ± 1.75
After treatment	2.89 ± 0.451
IgA (g/L)
Before treatment	4.88 ± 0.91
After treatment	0.82 ± 0.211
IgM (g/L)
Before treatment	1.49 ± 0.48
After treatment	0.24 ± 0.081
Rheumatoid factor	(-)
HLA-B27 (+), n (%)
Before treatment	85 (75.00)	0 (0.00)	< 0.001
After treatment	15 (13.27)1
ESR (mm/h)
Before treatment	48.83 ± 7.79	12.29 ± 2.73	< 0.001
After treatment	28.14 ± 4.321
BASDAI
Before treatment	4.98 ± 1.61
After treatment	0.93 ± 0.241
BASMI
Before treatment	4.26 ± 1.96
After treatment	0.71 ± 0.311

¹indicates compared with the research group before treatment, P < 0.05. BMI : Body mass index; CRP: C-reactive protein; IgG: Immunoglobulin G; IgA: Immunoglobulin A; IgM: Immunoglobulin M; HLA-B27: Human leukocyte antigen-B27; ESR: Erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASMI: Bath Ankylosing Spondylitis Metrology Index.